Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 7/20 | 0.53 |
| ▸ | JAK2 | O60674 | 3/20 | 0.53 |
| ▸ | JAK3 | P52333 | 3/20 | 0.53 |
| ▸ | SRPK1 | Q96SB4 | 3/20 | 0.47 |
| ▸ | SRPK2 | P78362 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16580779 | 0.88 | SRPK1 (0.51) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL16580738 | 0.88 | PTK2 (0.60) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL16580805 | 0.86 | SRPK2 (0.47) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL16580739 | 0.81 | SRPK1 (0.48) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL16570447 | 0.80 | SRPK1 (0.48) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL17958785 | 0.80 | SRPK1 (0.48) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL16570878 | 0.80 | PTK2 (0.56) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL16580807 | 0.80 | PTK2 (0.56) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL16570103 | 0.80 | PTK2 (0.54) | PTK2JAK2JAK3SRPK1SRPK2 | |
| SCHEMBL16570469 | 0.79 | SRPK1 (0.48) | PTK2JAK2JAK3SRPK1SRPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | PTK2 2/4885JAK2 9/4885JAK3 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.